Thursday, October 23, 2014   

Japan’s Takeda to appeal US$6b diabetes drug verdict
(04-08 15:53)

A US jury ordered Japan’s Takeda Pharmaceuticals to pay US$6 billion in punitive damages over a diabetes drug, but the country’s biggest drug-maker is challenging the move.
The District Court, Western District Louisiana, on Tuesday also ordered a US$3 billion penalty for co-defendant Eli Lilly, as well as US$1.5 million in compensatory damages.
The legal fight was over Actos, a drug used to treat diabetes, as causing a patient's bladder cancer.
Takeda Senior Vice President Kenneth Greisman said in a statement that Takeda disagrees with the verdict and plans post-trial motions and an appeal.
He said he empathized with the plaintiff but the drug did not cause his cancer.
The drug comes with warnings about serious side effects, including liver problems, broken bones and higher risk of bladder cancer. –AP

   
Other Business breaking news:
Manufacturing moving from China to US: survey (2 mins ago)
US billionaire's hedge fund dumps Sony stake (7 mins ago)
Hang Seng down by break (8 mins ago)
Nikkei weak by break (1 hr 14 mins ago)
Takata shares drop on report of US air bag probe (1 hr 15 mins ago)
China manufacturing sector grows faster in October: survey (1 hr 18 mins ago)
Sk Hynix logs all-time high Q3 earnings (1 hr 19 mins ago)
Apple computer sells for record US$905K in NY: Bonhams (1 hr 19 mins ago)
Heineken Q3 sales dip, but toasts 2014 outlook (10-22 18:38)
Boeing and Chinese firm to turn 'gutter oil' into jet fuel (10-22 18:37)

More breaking news >>

© 2014 The Standard, The Standard Newspapers Publishing Ltd.
Contact Us | About Us | Newsfeeds | Subscriptions | Print Ad. | Online Ad. | Street Pts

 


Home | Top News | Local | Business | China | ViewPoint | CityTalk | World | Sports | People | Central Station | Spree | Features

The Standard

Trademark and Copyright Notice: Copyright 2014, The Standard Newspaper Publishing Ltd., and its related entities. All rights reserved.  Use in whole or part of this site's content is prohibited.   Use of this Web site assumes acceptance of the
Terms of Use, Privacy Policy Statement and Copyright Policy.  Please also read our Ethics Statement.